Auriant Mining AB
Auriant Mining AB (publ.) applies for delisting from Nasdaq First North Growth Market
Auriant Mining AB (publ.) applies for delisting from Nasdaq First North Growth Market
Auriant Mining AB (the “Company”) announced on 14 October 2024 its plan to apply for delisting of the Company’s shares upon expiration of three months from the date of the abovementioned announcement. In accordance with the plan, the Company has today applied for delisting from Nasdaq First North Growth Market. The last day of trading in the Company’s shares on Nasdaq First North Growth Market will be announced as soon as the Company has received this information from Nasdaq.
For more information, please contact:
Danilo Lange, CEO
tel: +7 495 109 02 82
e-mail: d.lange@auriant.com
Company name: Auriant Mining AB
Short name: AUR
ISIN-code: SE0001337213
Website: www.auriant.com
Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in the Republic of Tyva, Zabaikalye and the Republic of Khakassia. The company has currently four assets, including two operating mines (Tardan and Alluvial at Staroverinskaya), one early stage exploration asset and one development asset.
Since July 19, 2010, Auriant Mining´s shares are traded on Nasdaq First North Growth Market under the short name AUR. For more information, please visit www.auriant.com. G&W Fondkommission is Certified Adviser to Auriant, for more information please visit www.gwkapital.se.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom